Despite sicker patients, response rates of teclistamab in a real-world study were similar to those from a pivotal clinical trial
Surprising outcome differs from previous results
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy